Boston Scientific announced a $14.5 billion cash‑and‑stock acquisition of Penumbra, bringing mechanical thrombectomy, embolization and neurovascular devices into Boston Scientific’s cardiovascular and neurovascular portfolio. The transaction, financed with cash and new debt, will give Boston Scientific access to Penumbra’s Lightning Bolt and Lightning Flash thrombectomy systems and embolization product lines. Company statements emphasize strategic fit in high‑growth vascular and neurovascular segments and the ability to scale Penumbra products through Boston Scientific’s international commercial reach.